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he drug & pharmaceutical industry play a vital role in the health care of  any 
country. Rapid growth of this industry requires further attention because even after 
64 years of independence, India, with around 15 % of the world population, 
accounts for less than 2 % of the drug production in the world. Annual per capita 
consumption of medicine in India is less than 2% of that in Japan. Health care expense in 
India is a dismal 0.8 % of GDP compared with 12.4 % in U.S.A. 6.5% in Japan and 6.2 % 
in the U.K, despite higher incidence of disease and malnutrition. The poverty and disease in 
India on one hand calls for higher standard of healthcare and pharmaceuticals production 
and on the other, stultifies the growth of industry due to poor affordability of an average 
Indian. The drug and pharmaceutical industry has, therefore, encountered a tough situation 
which most industry have always found  it difficult to provide abundant quantity of quality 
products at low prices. 
India has undertaken a major economic reform program since 1991. By virtue of this 
program, intensive changes have been made in the industrial policy of the Indian 
T 
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government relaxation of licensing rules, reduction in tariff rates, removal of restrictions on 
import etc. are among those which have been initiated in the early stages. The policy 
reforms had the objectives to make Indian industries as well as the entire economy more 
efficient, technologically up-to-date and competitive. This was done with the expectation 
that efficiency improvement, technological up-gradation and competitiveness would ensure 
Indian industry to achieve rapid growth. 
The Indian pharmaceutical sector is likely to witness major changes as a result of 
liberalization and pressure from GATT (General Agreement on Trade and Tariff) and WTO 
(World Trade Organization). Price controls are gradually being dismantled with less than 
50% of the drugs coming under the purview of DPCO. This number is likely to decrease 
further. In addition, as a signatory to WTO by 2005, India will be required to follow the 
same product patent laws governing the west. MNCs (Multinational Companies) in the past 
have been constrained in launching new products because of strict patents enforcement law 
governing their home countries. They are now keenly awaiting the protection of product 
patent in 2005, which will provide greater freedom to introduce new advanced international 
portfolio products. Indian pharmaceutical companies on the other hands are likely to suffer 
as a result of patent protection. It will become increasingly difficult for them to introduce 
new product without investing in basic research. Intensive research requires large 
investment that can only be recovered by spreading costs over a greater volume, thereby 
reducing average costs. However, because of high industry fragmentation and a lack of 
research, few domestic companies are able to reap the benefit of scale. Drug manufacturers 
are currently the most aggressive overseas investors of all Indian industries. They are 
pursuing foreign acquisitions due to their need to: improved global competitiveness, move 
up the value chain, create and enter new markets, increase their product offering, acquire 
assets(including research and contract manufacturing firms, in order to further boost their 
outsourcing capabilities) and new products, consolidate their market shares, and 
compensate for continued sluggishness in their home market. 
In view of greater openness in the Indian economy due to trade liberalization, the private 
sector can build and expand capacity without much regulation. There had been an 
investment boom in the manufacturing sector in the first half of 1990s (Uchikawa, 2001). 
The advocates of liberalization believe that these policy reforms will improve industrial 
growth and performance significantly while critics argue that total withdrawal of 
restrictions on several matters will have a negative effect on future growth and performance 
of the industry.  
As a part and parcel of self-appraisal, each and every industry is constantly engaged in the 
search for tools for assessing its own current performance. This performance can be judged 
suitably by comparing it with the various targets, past achievements and operative capacity. 
Business decision making and policy formulation mostly depend on economic indicators. In 
a capital scarce economy like India, manufacturing capacity utilization is a key indicator of 
economic performance which not only determines how much more output can be obtained 
by fuller utilization of existing capacity but also defines the required expansion of capacity 
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for a targeted output and also explains changes in investment, inflation, level of resource 
utilization etc.  Higher unutilized capacity implies slower growth rates. Therefore the 
estimation of capacity output and its utilization will be very useful to evaluate the variations 
in the performance of an industry over a period of time.  
Against this backdrop, this paper attempts to measure capacity utilization of the Indian 
pharmaceutical industry econometrically and analyze its trend over a period of 29 years-
from 1979-80 to2007-08 .The article also assesses the impact of liberalization on capacity 
utilization. Another objective of this paper is to assess the influence of various explanatory 
industrial characteristics on capacity utilization in a significant manner during the reform 
period.  
This study is conducted for the aggregates of an industry where capacity utilization has 
been taken as a yard stick in measuring performance assuming that all the firms in an 
industry behave alike and, therefore, industry level characteristics could be attributable to 
all the firms operating in that industry. It is not claimed that capacity utilization is the only 
yard stick for measuring the performance of an industry where there exist profitability and 
productivity variables for evaluating industrial performance. 
This paper is divided into the following sections: Section II depicts brief overview of 
pharmaceutical industry and conceptual issues related to capacity. Section III provides data 
base and methodology. Section IV estimates capacity and its utilization and interprets the 
results and Section V assesses and analyzes the impact of liberalization on capacity 
utilization and section VI analyzes the impact of various factors that influences capacity 
utilization. Section VII presents summary and conclusions. 
 
Brief overview of Pharmaceutical Industry 
The annual turnover of the Indian pharmaceutical industry is estimated to be about US $ 17 
billion (over Rs. 68,000 crore) during the year 2006-07. The share of export of drugs, 
pharmaceuticals and fine chemicals is more than Rs. 24,000 crore (around US $ 6 
Billion).This segment of Industry has shown tremendous progress in terms of infrastructure 
development, technology base and wide range of products. The industry now produces bulk 
drugs belonging to all major therapeutic groups requiring complicated manufacturing 
processes and has also developed excellent GMP (Good Manufacturing Practices) 
compliant facilities for the production of different dosage forms. The strength of the 
industry is in developing cost effective technologies in the shortest possible time for drug 
intermediates and bulk activities without compromising on quality. This is realized through 
the country's strengths in organic chemicals' synthesis and process engineering. 
The Indian pharmaceutical industry has come a long way from being almost non-existent in 
the 1970s to being one of the largest and most advanced pharmaceutical industries in the 
world. The domestic pharmaceutical output has increased at a CAGR (Compound annual 
growth rate) of 13.4%.Currently, the Indian pharmaceutical industry is valued at $8 billion 
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(approx).Globally, the industry ranks 4th in terms of volume and 13th in terms of value. It 
provides employment to millions and ensures that essential drugs are available to the vast 
population of India at affordable prices. Indian pharmaceutical industry has attained wide 
ranging capabilities in the complex field of drug manufacture and technology developed 
through a range of governmental incentives and the industry has been declared a knowledge 
based industry. This Industry is a highly organized sector and is extremely fragmented with 
severe price competitions and governmental price control. The major players in the Industry 
are Ranbaxy, Dr. Reddy’s Laboratories, Cipla, Sun Pharmaceutical Industries, Lupin Lab, 
Glaxo Smith Kline Pharmaceutical, Cadila Healthcare, Aventis etc.  
India has the highest number of manufacturing plants approved by US FDA, which is next 
only to that in the US. More than 85% of the formulations produced in the country are sold 
in the domestic market. Over 60% of India's bulk drug production is exported. India holds 
the lion's share of the world's contract research business, as activity in the pharmaceutical 
market continues to explode, over 15 prominent contract research organizations (CROs) are 
now operating in India attracted by her ability to offer efficient R&D on a low- cost basis. 
Thirty five percent of business is in the field of new drug discovery and the rest 65 percent 
of business is in the clinical trials arena. India offers a huge cost advantage in the clinical 
trials domain compared to Western countries. India got a major boost with the signing of 
Trade Related Intellectual Property Rights (TRIPS) under the General Agreement on Tariffs 
and Trade (GATT) in January 2005 with which it began recognizing global patents. The 
acceptance of patent laws and the rise of Contract Research and Manufacturing Sourcing 
(CRAMS) have led to the diversification of revenue streams, enabling the Indian 
pharmaceutical industry to experience high market growth.  
India is today recognized as one of the leading global players in pharmaceuticals. Europe 
accounts for the highest share of over 23% of Indian pharma exports followed by North 
America and Asia. Exports to the USA have crossed the land mark figure of US $1 billion 
during 2006-07. Internationally recognized as amongst the lowest-cost-producers of drugs, 
India holds fourth position in terms of volume and thirteenth position in terms of value of 
production in pharmaceuticals. It is estimated that by the year 2010, the Indian 
pharmaceutical industry has the potential to achieve over Rs.1,00,000 crore production of 
formulations and bulk drugs.  Exports constitute a substantial part of the total production of  
pharmaceuticals in India. The formulations contribute nearly 55% of the total exports and 
the rest 45% comes from bulk drugs. Pharmaceutical exports clocked $7.2 billion in 2007-
08, accounting for six per cent of the country’s total exports. Indian companies export drugs 
to over 200 countries, but the top 25 markets, which include the US, Germany, Russia, 
China and a few European and African countries, account for about half of the total. Indian 
drug makers exported medicines worth Rs 31,608 crore during April 2008-January 2009 
and exports shot up 30.7% as compared to last year due to a weak Indian currency and 
increased demand for low-cost generic medicines. US is the largest importer of drugs 
followed by Russia and Germany. Pharmaceutical industry accounts for about 2.91% of 
total FDI into the country. 
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Concept of Capacity 
The concept of capacity has played an important role in economic analysis. Unlike many 
well-defined concepts, capacity has been subjected to alternative definition and 
misconceptions. The economists’ definition differs from the engineers’ idea of capacity 
since what is technically possible may not be economically desirable. Simply, capacity 
output is defined as the maximum feasible level of output of the firm. An economically 
more meaningful definition of capacity output originated by Cassel (1937) is the level of 
production where the firms long run average cost curve reaches a minimum. As we consider 
the long run average cost, no input is held fixed. For a firm with the typical ‘U’ shaped 
average cost curve, at this capacity level of output, economies of scale have been exhausted 
but diseconomies have not set in. The physical limit defines the capacity of one or more 
quasi-fixed inputs. Klein defined capacity as the maximum sustainable level of output an 
industry can attain within a very short time, when not constrained by the demand for 
product and the industry is operating its existing stock of capital at its customary level of 
intensity.  Klein (1960) argued that long run average cost curve may not have a minimum 
and proposed the output level where the short run average cost curve is tangent to the long 
run average cost curve as an alternative measure of capacity output. This is also the 
approach adopted by Berndt and Morrison (1981). If technology exhibits constant return to 
scale, long run average cost curve is horizontal and the capacity level output is not defined. 
In this case, at the minimum point, the short run average cost curve is tangent to the long 
run average cost curve. This helps to determine the economic capacity output in the short 
run. 
We prefer choice theoretic model1  because it is firmly based in the behavioral concept of 
economic theory. The choice theoretic approach defines capacity output as the long run 
desired level of output given capital stock and input prices. The difference between 
engineering and economic capacity can be termed as intended excess capacity and that 
between economic capacity and actual output as unintended excess capacity. 
 
III. Data base and methodology: 
                                                 
1 Cassel (1937) first suggests that a firm’s capacity output is the minimum of the long run average cost 
curve. Klein (1960) and Friedman (1963) suggest capacity output as that output level at which long run 
and short run average cost curves are tangent.  Economic capacity is a short run concept. The fixed nature 
of some inputs like capital characterizes short run. For any amount of fixed input like capital, the output 
which can be obtained with the minimum long run cost method is capacity output which will require a 
higher cost method of production and therefore short run average cost of output is above the long run 
average cost curve except at the capacity output level. In the short run, higher cost methods are required 
to obtain additional output since only variable inputs may be increased. Therefore, a firm with fixed 
capital may choose to operate in the short run at a level of output that differs from the long run desired 
level and variation in CU is viewed as a short run phenomenon due to quasi-fixity of capital. 
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This paper covers a period of 29 years from 1979 – 80 to 2007 – 08. The entire period is 
divided into two phases as pre- reform period (1979 – 80 to 1990 – 91) and post- reform 
period (1991- 92 to 2007 – 08). 
Viewing variations in capacity utilization as a short-run phenomenon caused by the quasi-
fixed nature of capital, an econometrically tractable short-run variable-cost function which 
assumes capital as a quasi-fixed input has been used to estimate capacity utilization. 
Econometric Specification: 
Considering a single output and three input framework (K, L, E) in estimating capacity 
utilization where K, L and E are the capital, labor and energy inputs respectively, we 
assume that firms produce output within the technological constraint of a well behaved 2 
production function. 
 Y = f (K, L, E) where K, L and E are capital, labor and energy respectively. Since 
capacity output is a short-run notion, the basic concept behind it is that firm faces short-run 
constraints like stock of capital .Firms operate at full capacity where their existing capital 
stock is at long-run optimal level. Capacity output is that level of output which would make 
existing short-run capital stock optimal. 
 Rate of capacity utilization  is given as 
  CU = Y/Y* ……… (1) 
 Y is actual output and Y* is capacity output. Our model assumes that capacity 
utilization is a function of input prices, output and quasi-fixed capital . 
Therefore, in association with variable profit function, there exists variable cost function 
which can be expressed as  
 VC = f (PL, PE,   K, Y)……. (2) 
PL and PE are the price of labor and price of energy respectively and PK is the rental price of 
capital. 
 
Short run total cost (STC) function is expressed as  
 STC = f (PL,  PE,   K, Y) +  PK.. K…………….(3) 
 
 PK is the rental price of Capital. 
                                                 
2 A production function is considered to be well-behaved if it has positive marginal product for each input 
and it is quasi concave and also satisfies the conditions of monotonocity. Quasi-concavity required that 
the bordered Hessian matrix of first and second partial derivatives of the production function be negative 
semi definite.   
7
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Variable cost equation 3 which is variant of general quadratic form for (2) that provide a 
closed form expression for Y* is specified as  
  
VC = α0 + K-1 [ αK   + ½ βKK                       +  βKL. PL  + βKE .PE  ]  
 
+   PL ( αL + ½βLL .PL  + βLE .PE +  βLY .Y )  
+  PE ( αE + ½βEE .PE  + βEY .Y ) + Y(  αY + ½ βYY .Y ) ………. (4) 
K-1  is the capital stock at the beginning of the year which implies that a firm makes output 
decisions constrained by the capital stock at the beginning of the year. Capacity output (Y*) 
for a given level of quasi-fixed factor is defined as that level of output which minimizes 
STC. So, the optimal capacity output level, for a given level of quasi-fixed factors, is 
defined as that level of output which minimizes STC. So, at the optimal capacity output 
level, the envelop theorem implies that the following relation must exist. 
 
                           ∂STC/∂K  =   ∂VC/∂K  +   PK       =    0      --------------------- (5) 
                                                                                     
                      
In estimating Y*, we differentiate VC equation (4) w.r.t   K-1 and substitute expression in 
equation (5)                               
    Y* =        …………. 
(6) 
 
 
 
The estimates of CU can be obtained by combining equation (6) and (1). 
 
Description of data and variables: 
                                                 
3 Similar functional form has been previously estimated by Denny et al (1981). The variable cost function 
is based on the assumption that some input like capital cannot be adjusted to their equilibrium level. 
Therefore, the firm minimizes variable cost given the output and the quasi fixed inputs.  
K-1
Y 
– βKK. K-1 
( αK  +  βKL. PL  + βKE  .PE +  PK ) 
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A difficulty faced by researchers in conducting studies on capacity utilization in Indian 
industries is that available official data on Industrial capacities are quite unsatisfactory. The 
present study is based on industry-level time series data taken from several issues of Annual 
Survey of Industries, NAS and Economic Survey , Statistical abstracts (various issues), RBI 
bulletin etc. covering a period of 29 years commencing from 1979-80 to 2007-08. Selection 
of time period is largely guided by availability of data. 4 
Output and Variable cost: 
Details of methods employed for the measurement of variables are given in Appendix. 
Output is measured as gross output ( Appendix-A1) produced by manufactures suitably deflated 
by WIP index for manufactured product (base 1981 – 82 = 100) to offset the influence of 
price changes variable cost is sum of the expenditure on variable inputs (VC =  PL .L+ 
PE.E). 
Labor and price of labor:  
The total number of persons engaged in the pharmaceutical sector is used as a measure of 
labor inputs. Price of labor (PL) is the total emolument divided by number of laborers which 
includes both production and non-production workers (Goldar & others, 2004) 5 
Energy and Price energy: 
Deflated cost of fuel (Appendix-A2) has been taken as measure of energy inputs. Due to 
unavailability of data regarding periodic price series of energy in India, some 
approximations become necessary. We have taken weighted aggregative average price 
index of fuel (considering coal, petroleum and electricity price index, suitably weighted, 
from statistical abstract) as proxy price of energy. 6 
Capital stock and price of capital: 
Deflated gross fixed capital stock at 1981-82 prices is taken as the measure of capital input. 
The estimates are based on perpetual inventory method. (Appendix-A3) Rental price of capital is 
                                                 
4 Until 1988 – 89, the classification of industries followed in ASI was based on the National Industrial 
classification 1970 (NIC 1970). The switch to the NIC-1987 from 1989-90 and also switch to NIC1998 
requires some matching. For price correction of variable, wholesale price indices taken from official 
publication of CMIE have been used to construct deflators. 
 
5 One serious limitation of this assumption is that this does not take into account variations in quality and 
the composition of labor force. 
6 To compute the price of energy inputs, some studies have aggregated quantities of different energy 
inputs using some conversion factors (say British Thermal units or coal replacement etc.) and then take 
the ratio of expenditure on energy to the aggregate quantity of energy. This method is criticized because it 
assumes different types of energy inputs to be perfect substitutes. 
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assumed to be the price of capital (PK) which can be obtained from the ratio of interest paid 
to capital invested.  
Empirical Estimation of Capacity and its Utilization 
This section presents the results of a multiple regression analysis applied to measure 
capacity output. The variable cost equation as shown in equation (4) above has been 
estimated by the ordinary least square method (OLS). In Tables 1 and 2, we reproduce  
measure of capacity utilization  by economic measure for Indian pharma industry at 
aggregate level during pre and post-reform period respectively. From the estimate, we get a 
broad picture regarding variation in CU ratios.  
                                                             Table – 1 
  Trend in utilization of capacity of Indian Pharmaceutical industry at aggregate level. 
                              (Pre-reform period -1979-80 to 1991-92) 
Year Economic 
capacity  
output 
(Y*)(Cr. Rs) 
Actual 
output 
(Y) 
(Cr. Rs) 
Economic 
CU = Y/Y* 
Growth in 
capacity 
(%) 
Growth in 
output (%) 
1979-80 3142 2397 0.7629 - - 
80-81 3293 2803 0.8512 4.81 16.94 
81-82 3724 3361 0.9025 13.09 19.91 
82-83 3899 3649 0.9359 4.70 8.57 
83-84 3988 4069 1.0203 2.28 11.51 
84-85 4331 4312 0.9956 8.60 5.97 
85-86 4619 4175 0.9039 6.65 -3.18 
86-87 5064 5274 1.0415 9.63 26.32 
87-88 5312 5192 0.9774 4.90 -1.55 
88-89 5277 5421 1.0273 -0.66 4.41 
89-90 5598 5643 1.0080 6.08 4.10 
90-91 5989 5879 0.9816 6.98 4.18 
91-92 6739 5982 0.8877 12.52 1.75 
Average   0.9458 6.63 8.24 
         Source: Created by author from Annual Survey of Industries (several issues).                                             
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Table – 2 
Trend in utilization of capacity of Indian Pharmaceutical industry at aggregate level. 
                                      (Post-reform period-1991-92 to 2007-08) 
Year Economic 
capacity output 
(Y*)(Cr. Rs) 
Actual 
output (Y) 
(Cr. Rs) 
Economic Cu 
= Y/Y* 
Growth in 
capacity 
(%) 
Growth in 
output (%) 
91-92 6739 5982 0.8877 - - 
92-93 7058 6236 0.8835 4.73 4.25 
93-94 6172 6425 1.0410 -12.55 3.03 
94-95 8956 9293 1.0376 45.11 44.64 
95-96 9562 9142 0.9561 6.77 -1.62 
96-97 11438 10248 0.8960 19.62 12.10 
97-98 11726 10783 0.9196 2.52 5.22 
98-99 12452 12846 1.0316 6.19 19.13 
99-00 12789 12874 1.0066 2.71 0.22 
00-01 13589 13985 1.0291 6.26 8.63 
01-02 14578 14027 0.9622 7.28 0.30 
02-03 14129 11433 0.8092 -3.08 -18.49 
03-04 6739 5982 0.8877 -52.30 9.76 
04-05 14785 12549 0.8488 119.39 2.75 
05-06 14524 12894 0.8878 -1.77 10.57 
06-07 14623 14257 0.9750 0.68 5.93 
07-08 15743 15102 0.9593 7.66 4.25 
average   0.9423 9.95 6.92 
 Source: Created by author from Annual Survey of Industries (several issues).                                           
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From the analysis, we notice a number of important findings.  
First, it has been noticed that if capacity output is taken to be  the economic capacity 
derived from optimization process, the CU ratio could exceed one in more general cases 
indicating that production is to the right of the minimum point of short-run average total 
cost curve inducing cost-reducing net-investment. The implication of economic CU 
exceeding unity is that when there is a sudden increase in demand and immediate rise in 
price may not be feasible and in the short run, it might be necessary to operate at a point 
beyond the cost minimizing or profit maximizing point. This may so happen when firms 
attempt to maintain their reputation or market share, bear some of the cost burdens in the 
short run and oblige their customers through an increased supply of goods at unchanged 
prices. Our study shows that some of  the years, both in pre and post- reform periods, have 
shown CU exceeding one. This finding induces us to conclude that the firms could have 
reduced their production cost by moving to the minimum point of short run average cost 
curve.  
Second, economic measure of CU shows much more variation which is apparent from our 
study that the economic CU index ranges from about 0.76 to 1.04. Standard deviation of 
economic CU during pre and post-reform period are 0.081 and 0.072 respectively which 
signifies greater variation of economic CU in both segments of time period.  
Third, the estimate in table-1 and 2 shows that industry’s average economic CU slightly 
declined from 0.9458 to 0.9423 during post-reform period but reverse trends have been 
noticed in the average growth rate of capacity. During pre-reform period, capacity 
expansion was poor probably due to licensing restriction and demand grows at very rapid 
pace at that period but abolition of license raj during post-reform period paved the way for 
expansion of capacity abruptly. The growth rate in demand shows a declining trend during 
post-reform period as compared to pre-reform period. 
Fourth, it is important to note that the significant improvement in the rate of capacity 
utilization   of the industry was accomplished up to mid-90s despite substantial growth in its 
economic capacity indicating more efficient use of capital and other resources in this 
particular industry. 
Impact of Liberalization on Economic CU 
In investigating the issue of whether there exists any positive or negative impact of 
economic reforms on capacity utilization more precisely, we use a piecewise linear 
regression equation (popularly known as Spline function) where it is assumed that capacity 
utilization  increases linearly with the passage of time until the threshold time period ( t0 ). 
[Here, t0=1990-91 being last year of pre-reform period after which post-liberalization era 
begins] after which also it changes linearly with the passage of time but at a much steeper 
rate. Therefore, we have a piecewise linear regression consisting of two linear pieces or 
segments. The CU function changes it slope at the threshold value (t0=12). Given the data 
on capacity utilization, time period and the value of threshold level, the technique of 
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dummy variables can be used to estimate the slopes of the two segments of the piecewise 
linear regression. The piecewise linear regression equation is as follows: 
ln.Yt =  α + βt + β′(t – t0) Dt   
Result of the Regression Equation is as follows: 
ln .Yt = -0.1470 + 0.01215t – 0.0174Dt  
 (-3.46)      (2.59)         (-2.64) 
  R2 = 0.22  
Figures in the parenthesis are usually t values. Here β gives the slope of the regression line 
in pre-reform period which is positive and significant at 5% level. This implies that growth 
in capacity utilization shows positive trend immediately before liberalization starts.  
But as co-efficient of the difference between two time period is significant at 5% level and 
negative (coefficient being –0.0174), conclusive inference can be drawn in that 
liberalization has its significant negative impact on capacity utilization during post-reforms 
period. 
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                                                        Table – 3 
                  Trend in Growth rate of Capacity utilization (1979-80 to 2007-08)  
Pre- reform period(1979-80 to 1991-92) Pre- reform period(1991-92 to 2007-08) 
Year Growth rate (%) Year Growth rate (%) 
1979-80 - 91-92  -9.57 
80-81 11.57 92-93 -0.47 
81-82 6.03 93-94 17.83 
82-83 3.70 94-95 -0.33 
83-84 9.02 95-96 -7.85 
84-85 -2.42 96-97 -6.29 
85-86 -9.21 97-98 2.63 
86-87 15.22 98-99 12.18 
87-88 -6.15 99-00 -2.42 
88-89 5.11 00-01 2.24 
89-90 -1.88 01-02 -6.50 
90-91 -2.62 02-03 -15.90 
91-92 -9.57 03-04 9.70 
  04-05 -4.38 
  05-06 4.59 
  06-07 9.82 
  07-08 -1.61 
Average 1.57  0.83 
Source: Created by author from Annual Survey of Industries (several issues).    
 
It is visible from the estimated average growth rate in capacity utilization as shown in Table 
– 3 that there is a significant drop in average growth rate of capacity utilization from 1.57% 
in pre-reform period to 0.83% in post- reform period.  
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Factors influencing capacity utilization 
It is well recognized that utilization of capacity reflects the influences of markets supply 
and demand conditions, government policies, the degree of monopolization within an 
industry and the attitude of the managers of the firms in under developed countries (S. Paul, 
1974). Demand deficit, labor problem, transport bottlenecks, failure in power supply, 
mechanical/ maintenance trouble, strikes etc. are major cause responsible for under-
utilization of Industrial capacity in India. Apart from the above mentioned factors, industry 
characteristics like demand pressure, capital intensity, market concentration, scale of 
operation, etc. and policy variables influence capacity utilization rates of an industry. Paul 
(1974) found that industry characteristics explaining 40% of inter-industry variation in CU 
rates and policy variables explaining 32% of the inter-industry variation comprise nearly 
72% of the total inter-industry variations in CU. 
In this section, we have attempted to explain the nature of relationship between capacity 
utilization and different industrial characteristics (excluding other explanatory policy 
variables like import substitution, effective rate of protection etc. due to unavailability of 
reliable, comparable data) based on industry level and company wise time series data in the 
context of Indian pharmaceutical Industry. 
We analyze econometrically the effect of demand pressure, capital intensity, market 
concentration and scale of operation on capacity utilization. It employs multiple regression 
analysis technique (OLS) considering all explanatory variables in the same equation. 
Similar attempts were made earlier in the study of S. Paul (1974), Srinivasan (1992) and 
Goldar and Renganathan (1991).              
Independent variables considered in the present study are demand pressure, capital 
intensity, market concentration and scale of operation. These explanatory variables can be 
interpreted as under:  
Demand Pressure (GO): Demand Pressure is measured by growth rate of production over 
the time period. 
A positive relationship is expected between demand pressure and capacity utilization on the 
assumption that high demand pressure will enable the firms within a particular industry to 
make better utilization of productive capacity.             
Capital Intensity (K/L): Capital intensity is expressed as the productive capital used per 
person engaged. It is obtained by dividing productive capital by number of persons 
engaged. 
A positive relationship between capacity utilization and capital intensity is expected 
because high capital intensive firms of an industry enjoy better economies of scale inducing 
higher utilization rates. 
Market Concentration (CONR):  Market concentration is defined as the percentage of the 
sale value accounted for by the top 4 companies in the total sales of the industry. Top 4 
15
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companies have been chosen from CMIE data book in accordance with highest sales 
volume. 
Greater efficiency of some firms within the industry ensures better market concentration. A 
few firms capture a larger portion of market share due to their excellent efficiency resulting 
in increase in market concentration. Gradually, inefficient firms are wiped out of 
competition as a result of generating poor quality and charging high prices of products (due 
to increase in cost of production). Consequently, efficient firms expand their capacity as 
well as utilization rates to cope-up with the growing market demand thereby expecting a 
positive relationship between capacity utilization and market concentration. 
Scale of operation (MS): Scale of operation is defined as the value of its sale as a 
percentage of the total sales of the manufacturing industry. 
Capacity utilization can be influenced by the scale of operation of individual firms. As the 
scale of operation increases, there may be fewer bottlenecks and the lumpiness of the 
individual machine is more easily balanced, thereby increasing the average CU (Lecraw, 
D.J, P-145). Therefore, one would expect  a positive relationship between CU and scale of 
operation. 
In order to examine the effect of various forces (that affect CU) on capacity utilization, we 
estimate a linear multiple regression equation for all firms taken together using industry 
level and company wise time series data over a period of 29years. The single equation 
model with CU as dependent variables and demand pressure (GO), capital intensity (K/L), 
market concentration (CONR), scale of operation (MC) along with time variable (T) as 
explanatory variables is depicted as under :- 
U = α + β1GO + β2 (K/L) + β3 (CONR) + β4 (MS) + β5 T 
Where GO = Growth in production. 
K/L = Capital intensity.    
CONR = Concentration ratio. 
MS = Market share representing scale of operation. 
T =Time variable ,U = capacity utilization rate. 
The regression equation is estimated by ordinary least square (OLS) technique. CU is 
regressed separately on each independent valuable in different equations and then all 
explanatory variables are regressed in a single equation.  
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Table – 4 
Regression Result for Pharmaceutical Sector relating CU to GO, K/L, CONR, MS and T. 
Dependent Variable: Capacity Utilization 
Equation Intercept 
Term 
GO K/L CONR MS T R2 
1. -0.11 
(-0.197)* 
0.6277 
(2.627) 
4.794 
(1.96) 
1.415 
(1.94) 
0.8041 
(0.287) 
-0.064 
(-2.82) 
0.7426 
2. - 0.6054 
(3.06) 
4.55 
(2.26) 
1.30 
(2.82) 
0.44 
(0.222) 
-0.0632 
(-3.01) 
0.7412 
3. -0.0072 
(-0.018) 
0.5928 
(3.06) 
4.62 
(2.07) 
1.41 
(2.04) 
- -0.065 
(-3.04) 
0.7396 
4. 1.27 
(3.42) 
- - - -2.73 
(-0.87) 
-0.026 
(-1.94) 
0.3772 
5. 0.7839 
(6.53) 
0.5505 
(2.46) 
3.633 
(1.43) 
- - -0.0597 
(-2.43) 
0.6033 
6. 0.581 
(0.91) 
- 1.57 
(3.39) 
1.23 
(2.66) 
-2.95 
(-0.92) 
-0.03 
(-1.38) 
0.4888 
7. 0.69 
(1.19) 
- - 1.13 
(2.41) 
-2.93 
(-0.97) 
-0.0235 
(-1.78) 
0.46 
8. 0.9172 
(6.98) 
- 0.881 
(1.9) 
- - -0.0232 
(-0.97) 
0.3365 
9. 0.3789 
(0.786) 
- - 1.088 
(2.36) 
- -0.0127 
(-1.78) 
0.4144 
10 0.9417 
(19.15) 
0.41 
(1.96) 
- - - -0.0264 
(-3.24) 
0.5134 
Source: Created by author from Annual Survey of Industries & CMIE (several 
issues).    
*   t values are given in the parenthesis below 
GO =Growth in output indicating demand pressure 
K/L = Capital intensity 
CONR = Market concentration ratio  
MS= Market Share representing scale of operation 
T= Time variable  
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Table 4 above presents the estimated regression equations. We find a significant positive 
relationship between CU and demand pressure variable which supports our hypothesis. The 
coefficient of demand pressure variable is positive and is statistically significant in all 
equations at 0.05 level.  The major implication of this result is that as the growth rate of 
production indicating demand pressure increases, pressure is expected to come upon the 
firms within the industry that have idle capacities to enhance their utilization rates. This 
suggests that with growing demand for products, pharmaceutical industry has been 
gradually moving towards fuller utilization of capacity. 
The regression coefficient of capital intensity variable is all positive. The regression 
coefficient is statistically significant at 0.05 level in four equations, one at 0.10 level and 
another at 0.20 level. It indicates that pharma sector with relatively more capital intensive 
units tend to have higher rates of capacity utilization. Capital intensity is generally 
considered to be the proxy for  technology level. With the relaxation of import restrictions 
due to reform process, firms have resorted to more foreign capital – intensive technologies 
inviting huge opportunity cost of unused capital. The result suggests that capacity 
utilization rate is more in high capital intensive firms because unless these type of firms 
operate at higher utilization rate, they cannot recover the higher cost of capital.  
The estimated coefficient of market concentration variable indicates a positive relationship 
between market concentration and CU as coefficient in all equations are positive and 
statistically significant at 0.05 and 0.10 level. The result implies that increase in 
concentration ratio leads to higher utilization of capacity. 
This shows that higher seller concentration creates barriers on entry of new firms in the 
industry which assists concentrated firms to utilize its capacity at its fullest possible level 
thereby ensuring most effective utilization of scare capital resources.  
Our regression result reveals that scale of operation variable represented by market share is 
found to be confusing and statistically insignificant. This reveals that firms with sizable 
portion of market share do not have significant stimulation regarding utilization of its 
installed capacity. The result is contrary to our hypothesis.  
The explanation for not finding any significant relationship between CU and market share 
lies in the fact that there has not much change in market share of this sector over our study 
period, especially during 90’s.   
                                                         
Summary and findings 
As discussed earlier, India has undertaken various reform programs since 1991 in order to 
make the economy competitive and to meet the global challengers. This paper tries to 
examine the trends in capacity utilization in the Indian pharmaceutical sector during pre and 
post-reform period.  The major findings of the present study may be summarized below. 
First, there was a slight decrease in average capacity utilization rate in post-reform period as 
compared to pre-reform period. Secondly, annual average growth rate of capacity output 
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reveals increasing trend in growth rate at a much steeper rate but actual output shows 
declining trend . Therefore, the trend in capacity expansion reflects that capacity expanded 
more rapidly in post-reform period than in pre-reform period.  Thirdly, there is a sharp 
decline in the average annual growth rate of capacity utilization during the post-reform 
period in comparison with pre-reform period. Fourth, the estimates obtained  indicate that  
the liberalization process is found to have a significant adverse impact on capacity 
utilization since there is a fall in average growth rate of capacity utilization during the post-
reform period. Fifth, it is obvious from our estimate that utilization rate of capacity fell 
gradually after 1995-96. Removal of industrial licensing restriction might have encouraged 
the entrepreneurs to invest more and expand their plant capacity. Actual output being an 
indicator of public demand was expanding gradually up to first half of 90s and thereafter 
demand did not expand as much as increase of capacity. Sixth, the high correlation 
observed, in the sector, between the actual and capacity output ( r=0.97) suggests that a 
substantial part of capacity could have been kept unutilized by the firms within the industry 
to cope up with the unforeseen excessive demand shock coming from customers' front.  
From our regression analysis, it is evident that there exists a significant positive relationship 
between CU and the explanatory of variables such as demand pressure (GO) capital 
intensity (K/L) and market concentration (CONR). Although scale of operation variable 
reflected by sizable portion of market share was expected to exhibit a positive relationship, 
the result obtained from our analysis is contradictory as well as unsatisfactory. With regard 
to the “why’s” of what is revealed from our empirical result, it happens probably due to 
limitation and inadequacies of data. The present study lends strong support to earlier works 
conducted by Paul. S (1974) Goldar and Renganathan (1991), Srinivasan (1992).  
In a liberalized regime, abolition of  licensing rule encouraging new entrants, and at the 
same time, growing demand inducing existing firms to expand and utilize its capacity to the 
fullest possible, larger firms having greater access regarding import of capital goods 
coupled with domestic capital goods inducing higher capital intensity contributed towards 
favorable impact on CU. 
But there are some important lessons that can be learnt from our analysis in that high 
demand pressure, high capital intensity and high market concentration leading higher CU 
may have adverse impact on scare resources, employment and distribution system.  
In a nut shell, the empirical results presented in this study leave wider scope for further 
improvement and refinement. It is suggested that while making policy decisions on the 
basis of aggregate, the consideration of intra-sectoral analysis may be attempted in order to 
have more valuable results because generalization based on aggregative analysis sometimes 
fails to pave the way for improved decision making.  
In conclusion, as far as India’s pharmaceutical industry is concerned, various options are 
possible in the WTO regime. These are to:  (a) manufacture of patented generic drugs, (b) 
produce patented drugs under compulsory licensing or cross licensing,  (c) invest in R&D to 
engage in new product development, (d) produce patented and other drugs on contract 
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basis, (e) explore the possibilities of new drug delivery mechanisms and alternative use of 
existing drugs, and (f) collaborate with multinationals to engage in R&D, clinical trials, 
product development or marketing the patented product on a contract basis and so on.  
Besides these strategies, India’s strength lies in process development skills. This expertise 
utilized within the WTO framework with emphasis on quality standards will provide India a 
competitive advantage over other Asian countries.  
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APPENDIX: 
Appendix-A1: In industry level analysis, it is a recent practice to utilize gross output rather 
than value-added as a measure of product at the industry level. Jorgenson (1988) has shown 
that in a three input production framework, the contribution of intermediate input is the 
significant source of output growth in US economy. Intermediate input in our study consists 
of energy only. The yearly fuel consumed is taken as measure of energy input.  
Appendix-A2: Energy Inputs: Industry level time series data on cost of fuel of Indian 
Drug & pharmaceutical sector have been deflated by suitable deflator (base 1981-82 = 100) 
to get real energy inputs. An input output table provides the purchase made by 
manufacturing industry from input output sectors. These transactions are used as the basis 
to construct weight and then weighted average of price index of different sectors is taken. 
Taking into consideration 115 sector input – output table (1998 – 99) prepared by CSO, the 
energy deflator is formed as a weighted average of price indices for various input – output 
sectors which considers the expenses incurred by manufacturing industries on coal, 
petroleum products and electricity as given in I-O table for 1998 – 99. The WIP indices 
(based 1981 – 82) of Coal, Petroleum and Electricity have been used for these three 
categories of energy inputs. The columns in the absorption matrix for 66 sectors belonging 
to manufacturing (33 – 98) have been added together and the sum so obtained is the price of 
energy made by the manufacturing industries from various sectors. The column for the 
relevant sector in the absorption matrix provides the weights used.  
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AppendixA3: Capital Stock: The procedure for the arriving at capital stock series is 
depicted as follows : 
First, an implicit deflator for capital stock is formed on Net Fixed Capital Stock( NFCS) at 
current and constant prices given in NAS. The base is shifted to 1981-82 to be consistent 
with the price of inputs and output. 
Second, an estimate of net fixed capital stock (NFCS) for the registered manufacturing 
sector for 1970-71 (benchmark) is taken from National Accounts Statistics. It is multiplied 
by a gross-net factor to get an estimate of gross fixed capital stock (GFCS) for the year 
1970-71. The rate of gross to net fixed asset available from RBI bulletin was 1.86 in 1970-
71 for medium and large public Ltd. companies. Therefore, the NFCS for the registered 
manufacturing for the benchmark year (1970-71) as reported in NAS is multiplied by 1.86 
to get an estimate of GFCS which is deflated by implicit deflator at 1981-82 price to get it 
in real figure. In order to obtain benchmark estimate of gross real fixed capital stock made 
for registered manufacturing, it is distributed among various two digit industries (in our 
study, pharmaceutical industry) in proportion of its fixed capital stock reported in ASI, 
(1970-71). 
Third, from ASI data, gross investment in fixed capital in pharmaceutical industry is 
computed for each year by subtracting the book value of fixed capital  in previous year from 
that in the current year and adding to that figure the reported depreciation fixed asset in 
current year. (Symbolically, It = (βt - βt-1 + Dt ) / Pt) and subsequently it is deflated by the 
implicit deflator to get real gross investment. 
Fourth, the post benchmark real gross fixed capital stock is arrived at by the following 
procedure. Real gross fixed capital stock (t) = real gross fixed capital stock (t – 1) + real 
gross investment (t). The annual rate of discarding of capital stock (Dst) is assumed to be 
zero due to difficulty in obtaining data regarding Dst.   
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